The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

Sub: Disclosure pursuant to Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in relation to pledge of equity shares of For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: October05, 2026 Part A Annexure Disclosures under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Part-A-Details of the Acquisition Name of the Target Company (TC) BLISSGVSPHARMALIMITED Name(s) of the acquirer and Persons Acting in Concert Catalyst Trusteeship Limited acting as Debenture (PAC) with the acquirer Trustee on behalf of Debenture holders Whether the acquirer belongs to Promoter/Promoter No group Name(s) of the Stock Exchange(s) where the shares of BSE Limited and National Stock Exchange of India TC are Listed Limited Details of the acquisition as follows Number % w.r.t. total % w.r.t. total share/voting diluted capital share/voting wherever capital of the TC applicable(*) (**) Before the acquisition under consideration, holding of acquirer along with PACs of: a) Shares carrying voting rights - - - b) Shares in the nature of encumbrance - - - (pledge/lien/non-disposal undertaking/others) c) Voting rights (VR) otherwise than by equity - - - shares d) Warrants/convertible securities/any other - - - instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e) Total (a+b+c+d) - - - Details of acquisition a) Shares carrying voting rights acquired - - - b) VRs acquired otherwise than by equity shares - - - c) Warrants/convertible securities/any other - - - instrument that entitles the acquirer to receive shares carrying category) acquired d) Shares in nature of encumbrance (pledge / lien 5,09,84,595 47.95% 46.77% / non-disposal undertaking / others) e) Total (a+b+c+d) 5,09,84,595 47.95% 46.77% After the acquisition, holding of acquirer along with PACs of: a) Shares carrying voting rights - - - b) VRs otherwise than by equity shares - - - c) Warrants/convertible securities/any other - - - instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in nature of encumbrance 5,09,84,595 47.95% 46.77% (pledge/lien/non-disposal undertaking/others) e) Total (a+b+c+d) 5,09,84,595 47.95% 46.77% Mode of acquisition (e.g. open market / public issue / By way of pledge of equity shares of the Target rights issue / preferential allotment / inter-se transfer/ Company in favour of Catalyst Trusteeship Limited encumbrance, etc.) Salient features of the securities acquired including Pledge over 5,09,84,595 equity shares of the Target time till redemption, ratio at which it can be converted Company BLISS GVS PHARMA LIMITED in favour of into equity shares, etc. Catalyst Trusteeship Limited acting as Debenture Trustee on behalf of Debenture holders. Date of acquisition of/ date of receipt of intimation of 30thSep, 2026 allotment of shares / VR/ warrants/convertible [i.e. (a) 5,09,84,595Equity Shares on Sep 30, 2026; and securities/any other instrument that entitles the acquirer to receive shares in the TC. Equity share capital / total voting capital of the TC INR 10,63,30,472(10,63,30,472shares of Face value of before the said acquisition Re. 1 each) Equity share capital/ total voting capital of the TC INR 10,63,30,472(10,63,30,472shares of Face value of after the said acquisition Re. 1 each) Total diluted share/voting capital of the TC after the INR 10,90,11,222(10,90,11,222sharesof Face value of said acquisition Re. 1 each) Signature of the acquirer: For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: October05, 2026